BMJ2d
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
41 St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis ...
BMJ5d
Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era
Correspondence to Ping-Hsuan Hsieh, Health Economics and Health Technology Assessment, University of Glasgow Institute of Health and Wellbeing, Glasgow G12 8RZ, UK; p.hsieh.1{at}research.gla.ac.uk ...
BMJ8d
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Correspondence to Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden D-01307, Germany; martin.aringer{at}uniklinikum-dresden.de; Dr ...
BMJ8d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ10d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ11d
Axial spondyloarthritis
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common ...
BMJ11d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ12d
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent ...
BMJ14d
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
Objective To investigate the association between baseline disease activity and the occurrence of flares after adalimumab tapering or withdrawal in patients with rheumatoid arthritis (RA) in sustained ...
BMJ14d
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled ...
BMJ25d
Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...
BMJ26d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...